Skip to Main Content
Phase I

A Phase 1 Open-Label, Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-766 in Patients With Metastatic Castration-Resistant Prostate Cancer

  • Study HIC#:2000030751
  • Last Updated:05/24/2022

This study will evaluate the safety and efficacy of ARV-766 in men with metastatic castration-resistant prostate cancer.

  • Start Date05/23/2022
  • End Date01/01/2100

Trial Purpose and Description

The study will evaluate ARV-766 given once or twice daily to cohorts of patients in escalating doses. Each dose level will have safety assessed and if found safe and tolerable, the next cohort of patients will be enrolled at a higher dose level. Increasing dose levels will be evaluated until the highest safe dose is identified. Patients treated at lower doses may increase to the next higher dose level once it is determined to be safe, provided they have been on their current dose for 28 or more days and have no major side effects.

Eligibility Criteria

Inclusion Criteria:

  • Histological, pathological, or cytological confirmed diagnosis of adenocarcinoma of the prostate.
  • Progression on at least 2 prior approved systemic therapies for metastatic prostate cancer (at least one must be a second-generation androgen inhibitor, e.g., abiraterone, enzalutamide, darolutamide, apalutamide).
  • Progressive mCRPC
  • Ongoing androgen deprivation therapy (ADT) with a gonadotropin releasing hormone analog or inhibitor, or orchiectomy (surgical or medical castration).
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

Exclusion Criteria:

  • Known symptomatic brain metastases requiring steroids (above physiologic replacement doses).
  • Active inflammatory gastrointestinal disease, chronic diarrhea, known diverticular disease, or previous gastric resection or lap band surgery.
  • Radiation therapy within 4 weeks of first dose of study drug or prior irradiation to >25% of the bone marrow.
  • Receipt of an investigational drug(s) within 4 weeks prior to anticipated first dose

For more information about this study, contact: